Pfizer gets new rebuff from NICE for cancer drug
LONDON (Reuters) - Pfizer suffered a second rejection in two days from health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service.
The National Institute for Health and Clinical Excellence (NICE) said on Thursday the new treatment was not a cost-effective use of National Health Service resources.
The decision follows a similar rebuff for Pfizer's lung cancer drug Xalkori on Wednesday.
In both cases, the NICE recommendations are preliminary and subject to further consultation.
- Tweet this
- Share this
- Digg this
- Pro-independence Scots narrow gap to victory ahead of vote - poll
- UK's fate in the balance as poll shows record support for Scottish independence
- Child abuse revelations divide "most shameful town in Britain"
- Kremlin adviser says military strategy to reflect Ukraine crisis, NATO expansion - RIA
- Russian forces strengthening positions in Ukraine - Kiev military